Kornimate/medical-research-clean huggingface dataset:
effects of whole body vibration in subacute stroke patients

Conditions: Stroke

Summary: the overall aim of the proposed study is to determine whether whole body vibration is beneficial in promoting bone turnover, physical fitness and neuromotor performance in patients with subacute stroke.

brief periods of whole body vibration (wbv) have been shown to improve bone density in post-menopausal women and children with cerebral palsy. in addition to the apparent benefits on bone health, wbv has been shown to increase muscle strength, postural control, muscular blood flow and oxygen uptake in various populations. therefore, wbv can potentially be used as a tool to improve muscle strength, balance, and cardiovascular performance, especially for those with relatively low level of functioning. stroke patients are therefore possible beneficiaries of wbv, as they often demonstrate muscle weakness, balance deficits, and poor cardiovascular function, in addition to bone loss. only one pilot study has examined the effects of wbv in stroke patients. van nes et al.showed that postural stability in chronic stroke patients is improved after a few minutes of wbv at 30hz and 3mm amplitude. the overall aim of the proposed study is to determine whether whole body vibration is beneficial in promoting bone turnover, physical fitness and neuromotor performance in patients with subacute stroke.

Eligibility criteria:
inclusion criteria: * diagnosis of stroke * medically stable * able to understand simple verbal commands * of chinese origin exclusion criteria: * previous stroke in addition to the current admission * other neurological conditions, in addition to stroke * significant musculoskeletal or vascular conditions in the lower extremity * metal implants in the lower extremity * previous fracture in the lower extremity * are taking or were taking bone resorption inhibitors

Keywords: stroke bone gait muscle vibration motor balance
drug-eluting stents to treat unprotected coronary left main disease

Conditions: Coronary Disease

Summary: the purpose of this study is to evaluate the efficacy of two different drug-eluting stents (everolimus and zotarolimus-eluting) for treatment of unprotected left main coronary artery disease.

restenosis in the left main coronary artery may have severe consequences given the large proportion of the myocardium compromised in this condition, and, in several studies, it has been linked to the 6-month mortality after the index procedure. drug-eluting stents have reduced the restenosis rate and the need for target vessel revascularization not only in simple lesion but also in high risk subsets of patients and lesions such as diabetics, long lesions or bifurcations. there are no data about their efficacy in left main coronary artery disease. thus, the aim of this study is to investigate the performance of two different drug-eluting stents (everolimus and zotarolimus-eluting) in left main coronary lesions.

Eligibility criteria:
inclusion criteria: * patients older than age 18 with ischemic symptoms or evidence of myocardial ischemia in the presence of ≥ 50 % stenosis located in unprotected lmca who are unable to undergo cabg because of cardiac surgeons' refusal (poor surgical candidates) or their own unwillingness. * pretreatment with a loading dose of 600 mg clopidogrel. * informed, written consent by the patients or her/his legally-authorized representative for participation in the study. exclusion criteria: * cardiogenic shock. * st-segment elevation acute myocardial infarction (st-segment ≥ 0.1 mv elevation in ≥ 2 contiguous ecg leads persisting for at least 20 minutes) within 48 hours from symptom onset. * in-stent restenosis. * malignancies or other comorbid conditions with life expectancy less than one year or that may result in protocol non-compliance. * prior coronary artery bypass surgery with revascularization of lad and/or lcx. * planned staged pci procedure within 30 days from index procedure or prior pci within the last 30 days. * an elective surgical procedure is planned that would necessitate interruption of clopidogrel during the first six months post enrollment. * known allergy to the study medications: aspirin, clopidogrel, uhf; sirolimus, paclitaxel; true anaphylaxis after prior exposure to contrast media. * pregnancy (present, suspected or planned). * patient's inability to fully cooperate with the study protocol.

Keywords: drug eluting stent left main disease
effectiveness of vagus nerve stimulation in individuals with tension-type headache

Conditions: Tension-Type Headache

Summary: it is planned to examine the effect of vagus nerve stimulation on headache symptoms in individuals with tension-type headache.

tension-type headache is the most common primary headache, usually bilateral, characterized by oppressive and squeezing pain of mild or moderate intensity, unchanged by physical activity. it affects approximately 80% of the population and has a point prevalence of 42% in the general population. there are various pharmacological and non-pharmacological treatment methods for tension-type headache. one of the non-pharmacological treatment methods may be vagus nerve stimulation (vns). vns can affect healing processes by regulating the autonomic nervous system and reduce symptoms in tension-type headache.

Eligibility criteria:
inclusion criteria: * individuals with tension-type headache according to the international classification of headache disorders (ichd-3) criteria, * individuals between the ages of 18-65, exclusion criteria: * history of trauma or surgery to the head and neck region, * presence of lesions or metal implants in the application area, * uncontrolled hypertension/abnormal ecg results/history of myocardial infarction/pacemaker and similar cardiovascular disease history/suspicion, * pregnancy or suspicion, * other primary and secondary headache types, * individuals who received physiotherapy in the last 6 months,

Keywords: tension-type headache vagus nerve stimulation
long-term safety study of mp-513 as monotherapy or in combination with sulfonylurea in japanese type 2 diabetic patients

Conditions: Type 2 Diabetes Mellitus

Summary: the purpose of this study is to evaluate the safety and efficacy of mp-513 (teneligliptin) as monotherapy or in combination with sulfonylurea (glimepiride) in japanese patients with type 2 diabetes for 52 weeks administration.


Eligibility criteria:
inclusion criteria: * in case of combination therapy with sulfonylurea, patients who has been receiving a stable dose and regimen of sulfonylurea for diabetes over 12 weeks before administration of investigational drug * patients who are under dietary management and taking therapeutic exercise for diabetes over 12 weeks before administration of investigational drug * hba1c criteria: * monotherapy: 6.9% - 10.5% * combination therapy with sulfonylurea: 7.4 - 10.5% * patients who were not administered diabetes therapeutic drugs prohibited for concomitant use within 12 weeks before administration of investigational drug. exclusion criteria: * patients with type 1 diabetes, diabetes mellitus caused by pancreas impairment, or secondary diabetes (cushing disease, acromegaly, etc) * patients who are accepting treatments of arrhythmias * patients with serious diabetic complications * patients who are the excessive alcohol addicts * patients with severe hepatic disorder or severe renal disorder * patients who are pregnant, lactating, and probably pregnant patients, and patients who can not agree to contraception

Keywords: dpp-iv inhibitor
a 24-week open-label study of kps-0373 in patients with spinocerebellar degeneration (scd)

Conditions: Spinocerebellar Degeneration

Summary: the purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of kps-0373 in scd patients (experience of clinical trials of kps-0373)


Eligibility criteria:
inclusion criteria: * japanese scd patients with ataxia (experience of clinical trials of kps-0373) exclusion criteria: * patients with secondary ataxia * patients with clinically significant hepatic, renal, or cardiovascular dysfunction * discontinuations in another clinical trials caused by side effects

Keywords: spinocerebellar degeneration (scd) thyrotropin-releasing hormone (trh) spinocerebellar ataxia (sca)
safety and immunogenicity of 2 or 3 doses of menacwy conjugate vaccine in healthy infants and the effects of a booster dose of menacwy administered in the second year of life

Conditions: Meningococcal Disease; Meningococcal Meningitis

Summary: the purpose of this study was to assess immunogenicity of a 3-dose versus 4-dose infant vaccination schedule including kinetics of immune response in the early phases of the series.


Eligibility criteria:
inclusion criteria: * infants of both genders who are in generally good health will be eligible for this study. for infants to be enrolled, the parents/legal representatives need to provide written informed consent and to be available for all study visits. exclusion criteria: * serious, acute, or chronic illnesses are reasons for exclusion.

Keywords: meningococcal acwy conjugate vaccine meningitis infants persistence
efficacy and safety of hrs9531 injection in obese subjects without diabetes

Conditions: Overweight or Obesity

Summary: to evaluate the efficacy and dose-response relationship of hrs9531 injection compared with placebo in reducing body weight in obese subjects without diabetes after 24 weeks of treatment.


Eligibility criteria:
inclusion criteria: 1. able and willing to provide a written informed consent; 2. male or female subjects, 18-65 years of age at the time of signing informed consent; 3. at screening visit, 28.0 ≤bmi≤ 40.0 kg/m2; 4. diet and exercise control for at least 3 months before screening visit, and less than 5 kg self-reported change within the last 3 months. exclusion criteria: 1. presence of - clinically significant lab or ecg results that may affect the evaluation of the efficacy or safety of the study drug at screening visit; 2. uncontrollable hypertension; 3. phq-9 score ≥15; 4. medical history or illness that affects your weight; 5. history of diabetes; 6. acute infection, acute trauma, or medium to large surgery within 1 month prior to screening; 7. history of acute cardiovascular and cerebrovascular diseases within 6 months prior to screening; 8. any organ-system malignancies developed within 5 years except for cured local basal cell cancer of the skin and in-situ cancer of the cervix; 9. confirmed or suspected depression, bipolar disorder, suicidal tendencies, schizophrenia, or other serious mental illness; 10. history of alcohol and/or substance abuse or drug abuse within 1 year prior to screening; 11. use of any medication or treatment that may have caused significant weight change within 3 months; 12. history of bariatric surgery; 13. known or suspected hypersensitivity to trial product(s) or related products; 14. participation in other clinical trials for any weight-loss indication within 3 months prior to screening, or participation in other clinical trials for any drug or medical device within 1 month prior to screening; 15. history of blood donation or blood loss in the 3 months before screening, or blood transfusion in the 2 months before screening; 16. surgery is planned during the trial; 17. mentally incapacitated or speech-impaired; 18. female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using an adequate contraceptive method; 19. researchers and relevant staff of the research centre or other people directly involved in the implementation of the programme, and their immediate family members.
a comparative study of supine position and the head elevated position on the level of sensory block after spinal anesthesia in morbidly obese parturient undergoing elective cesarean delivery

Conditions: High BMI

Summary: the sniffing position defined as neck flexion with upper cervical extension, is traditionally recommended for general anesthesia induction, as it improves laryngoscopic views. however, the head elevation beyond the sniffing position, also known as ramped position or head elevated laryngoscopy position, usually achieved by specially designed pillows such as the oxford head elevating laryngoscopy pillow (alma medical,oxford, uk) or the troop® elevation pillow (mercury medical, clearwater, fl, usa)has been shown to not only increase respiratory reserve but also to improve laryngeal views in patients undergoing bariatric surgery. additionally it helps in pre-oxygenating the patient more efficiently by keeping the airway patent and provides easier bag-mask ventilation. it may also benefit the term parturient in a similar way by improving functional residual capacity (frc), ventilation and comfort. however, this positon may affect the cephalad spread of the intrathecal local anesthetic. two earlier studies looked at the intrathecal local anesthetic spread in obstetric patients when placed in the head elevated laryngoscopy position, and both suggested poor cephalad spread, with patients requiring higher supplementation. however, both studies excluded morbidly obese patients. the investigators hypothesized that in obese parturients with bmi more than or equal 40, higher intra-abdominal pressures and possibly lower csf volumes will counteract the poor cephalad spread associated with this position. the aim of this study is to determine the effect of a ramped position on intrathecal local anesthetic spread in the morbidly obese term parturients with bmi more than or equal 40 undergoing elective cesarean delivery(cd).


Eligibility criteria:
inclusion criteria: * age 18yrs of age or more * bmi 40 or more and more than or equal 37 weeks of gestation * elective cd * consented for neuraxial anesthesia * singleton fetus * asa class 3 (no co-morbidities except morbid obesity, gestational diabetes, and gestational hypothyroidism) exclusion criteria: * age \<18 years * bmi less than 39.9 and \<37 weeks of gestation * parturient preference for general anesthesia or contraindication to neuraxial anesthesia * women with comorbidities other than obesity, gestational diabetes or gestational hypothyroidism. * women in active labor (\>3 cm dilated with regular uterine contractions) * emergency cd * possible uterine over-distension or under-distension (e.g. polyhydramnios, estimated fetal weight \>4 kg by ultrasound scan, or oligohydramnios or concern for fetal iugr) * maternal height \ 180 cm. * patients for which more than 2 minutes is taken in positioning after anesthesia induction (time 0).
comparison of medical and surgical treatment of uncomplicated acute appendicitis in children

Conditions: Appendicitis

Summary: several prior studies have demonstrated that medical management of acute appendicitis in adults is a safe first-line therapy option. this study aims to determine whether non-operative management of uncomplicated acute appendicitis with antibiotics is non-inferior to operative management in a pediatric population. this study will be a randomized controlled trial comparing non-operative management with antibiotics to surgical management of uncomplicated acute appendicitis. the hypothesis is that antibiotics are not worse than surgery for the treatment of uncomplicated appendicitis in children.


Eligibility criteria:
inclusion criteria: * first episode of appendicitis * pain \< 48 hours * white blood cell count \< 18,000 * temperature \< 103º f * radiographic evidence of acute appendicitis on ultrasound or ct without evidence of perforation * appendiceal diameter \< 11 mm * ability to take oral antibiotics exclusion criteria: * prior antibiotic treatment for appendicitis * presence of medical condition prohibiting surgical therapy * radiographic or clinical evidence of abscess or perforation * appendiceal mass, positive pregnancy test * other diagnosis equally as likely as appendicitis * pain for ≥ 48 hours, white blood cell count ≥ 18,000, temperature ≥ 103º f, or appendiceal diameter ≥ 11 mm * inability to take oral antibiotics.
optimization and harmonization of advanced mri sequences

Conditions: Dementia Frontal; Dementia Alzheimers; Lewy Body Variant of Alzheimer Disease; Neuro-Degenerative Disease

Summary: development of a shared multimodal mri protocol for the definition and quantification of imaging biomarkers in ad, dlb, fdt dementias, especially white matter alterations.

development of a shared multimodal mri protocol for the definition and quantification of imaging biomarkers in ad, dlb, fdt dementias, especially white matter alterations.

Eligibility criteria:
inclusion criteria: for patients * accident cases * time of onset of not more than 24 months * clinical dementia rating scale (cdr) \<=2; * moca\<=17 for controls absence of complaints of cognitive disorders and/or neurological/neuropsychological visits for the evaluation of such disorders; * cdr = 0; * moca\>=27. for all age \>= 50 and \<= 80; * hachinski ischemic scale - 7 items \< 2; * visual and/or auditory acuity sufficient to carry out the neuropsychological assessment; * if on neuropsychopharmacological therapy, stability for 4 weeks before the start of the study. exclusion criteria: for all * any uncontrolled medical condition or neurological/neurodegenerative disease that, in the opinion of the recruiting physician, could contribute to the individual's cognitive impairment \[e.g., kidney disease, liver disease, brain tumor, alcohol or drug abuse, abnormal thyroid function, hydrocephalus normotensive, vascular dementia, neurocognitive disorder due to head trauma (according to the diagnostic criteria of the dsm v)\]; * transient ischemic attack or stroke during the 12 months preceding screening; history of unstable angina, myocardial infarction, heart failure (new york heart association class iii or iv), or clinically significant heart rhythm disturbances documented within one year of screening; * history of malignant tumor disease, except: cancer in remission for more than 5 years since screening; prostate cancer in situ; * history of surgically treated squamous cell carcinoma or basal cell carcinoma; * impaired liver function or liver failure; * history or evidence of autoimmune disease considered clinically significant by the doctor or requiring the chronic use of corticosteroids or other immunosuppressive drugs; * clinically significant systemic illness or infection within 30 days of screening; comorbidity for primary psychiatric or neurological disorders; * absence of an informant (partner, relative, adult child or friend) who knows the subject well enough to be able to provide reliable information on his cognitive and functional abilities. * contraindication to carrying out the mri exam.
a prospective cohort study for patients with adrenal diseases

Conditions: Adrenal Adenoma; Cushing Syndrome; Pheochromocytoma; Adrenal Incidentaloma; Adrenocortical Carcinoma; Primary Hyperaldosteronism

Summary: the purpose of this study is to investigate the pathologic features, complications, and prognostic factors of functioning adrenal adenoma and suggest follow-up algorithms for adrenal incidentaloma.

the investigators will recruit 150 patients annually for 10 years (adrenal incidentaloma 100 patients, pheochromocytoma 15 patients, primary aldosteronism 25 patients, adrenal cushing syndrome 10 patients, adrenocortical carcinoma 2 patients) and perform hormonal, biochemical, imaging exam according to each disease's clinical guidelines. based on this, the investigators will identify pathologic features, complications, and prognostic factors of each disease.

Eligibility criteria:
inclusion criteria: * adults, male or female aged 19 years or older * newly diagnosed with adrenal disease such as adrenal incidentaloma, pheochromocytoma, primary aldosteronism, adrenal cushing syndrome, adrenocortical carcinoma exclusion criteria: * previous or current history of adrenal diseases * using oral or intravenous steroids * history of major depressive disorder * history of chronic alcoholics * history of any cancer with suspicious adrenal metastasis * those with acute illness (ex- patients with acute coronary syndrome within 4 weeks, acute febrile disease)

Keywords: algorithms adrenal adenoma cushing syndrome pheochromocytoma adrenal incidentaloma adreocortical carcinoma primary hyperaldosteronism
the israeli mguard registry

Conditions: Ischemic Heart Disease; Acute Coronary Syndrome; Acute Myocardial Infarction

Summary: the objective of the israeli mgurad registry is to evaluate the 'real world' clinical performance of the inspiremd mguard coronary stent system

a prospective, observational, multicenter registry the primary objective of this registry is to document the safety and overall clinical performance of the mguard coronary stent system in a "real world" patient population requiring stent implantation. the secondary objective is to assess the event rate in patient subgroups with specific clinical indications and/or vessel and/or lesion characteristics.

Eligibility criteria:
inclusion criteria: * patient is \> 18 years of age * the patient has consented to participate by signing the "patient informed consent form" * patient is suitable for implantation of one or more mguard stent system in one or more target lesions * target lesion(s) are according to the indications for use and israeli regulatory approval of the mguard stent system * the patient is willing and able to cooperate with registry procedures and required follow up exclusion criteria: * heavily calcified target lesions * target lesions with side branch bigger then 2.5mm * target lesions which are distal to newly stented lesion (less than 1 month). * women with known pregnancy * current medical condition with a life expectancy of less than 12 months * patients with medical conditions that preclude the follow-up as defined in the protocol or that otherwise limits study participation

Keywords: distal embolization thrombotic lesions ami acs svg
cryoballoon atrial fibrillation ablation registry

Conditions: Atrial Fibrillation

Summary: this is a prospective registry of atrial fibrillation cryoablation in the russian federation. this study is observational, prospective, multicenter, open-label

the purpose of this registry is to describe characteristics of patients undergoing cryoballoon ablation, diversity of cryoablation techniques among different centers; to evaluate efficacy and safety of the procedure in the centers with different levels of experience.

Eligibility criteria:
inclusion criteria: * the indications for catheter ablation of atrial fibrillation * signed informed consent to participate in the register * patients undergoing cryoballoon ablation exclusion criteria: * left atrial thrombosis
human papillomavirus education programs

Conditions: Human Papillomavirus-Related Carcinoma

Summary: this clinical trial aims to implement a culturally-tailored educational outreach actives with the goal of increasing knowledge of human papillomavirus (hpv) types that can lead to cancer and uptake of the available vaccine. the initiative also addresses barriers to vaccination and refer people to sites where they can get the hpv vaccine (e.g., private doctor offices, community health clinics, school-based health centers, and health departments). the hpv education program may help increase hpv vaccination rates and ultimately prevent hpv-related cancers.

primary objective: i. to implement culturally tailored educational outreach activities with the goal of increasing knowledge of hpv types that can lead to cancer and uptake of the available vaccine. outline: participants attend educational session about hpv-related cancers, screening, and hpv vaccination and guidelines and receive informational infographic handout on hpv vaccination. participants also complete surveys pre and post education session over 5 minutes each to assess hpv vaccination status among children of participants, hpv knowledge, and intentions to get the hpv vaccination, and screening among participants. participants participate in surveys over telephone or face-to-face at 3 and 6 months.

Eligibility criteria:
inclusion criteria: * 18 years of age and older * from ohio